Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does SUNITINIB MALATE Cause Neoplasm progression? 1,920 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 1,920 reports of Neoplasm progression have been filed in association with SUNITINIB MALATE (Sunitinib malate). This represents 8.9% of all adverse event reports for SUNITINIB MALATE.

1,920
Reports of Neoplasm progression with SUNITINIB MALATE
8.9%
of all SUNITINIB MALATE reports
545
Deaths
558
Hospitalizations

How Dangerous Is Neoplasm progression From SUNITINIB MALATE?

Of the 1,920 reports, 545 (28.4%) resulted in death, 558 (29.1%) required hospitalization, and 46 (2.4%) were considered life-threatening.

Is Neoplasm progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for SUNITINIB MALATE. However, 1,920 reports have been filed with the FAERS database.

What Other Side Effects Does SUNITINIB MALATE Cause?

Death (4,385) Diarrhoea (3,044) Fatigue (2,865) Nausea (2,032) Disease progression (1,745) Decreased appetite (1,676) Asthenia (1,651) Vomiting (1,331) Dysgeusia (1,226) Malaise (1,202)

What Other Drugs Cause Neoplasm progression?

PALBOCICLIB (10,885) CYCLOPHOSPHAMIDE (1,588) CARBOPLATIN (1,370) AXITINIB (1,315) DOXORUBICIN (1,276) LETROZOLE (1,225) PACLITAXEL (1,180) CRIZOTINIB (1,161) VINCRISTINE (1,106) GEMCITABINE (960)

Which SUNITINIB MALATE Alternatives Have Lower Neoplasm progression Risk?

SUNITINIB MALATE vs SUTENT SUNITINIB MALATE vs SUTIMLIMAB-JOME SUNITINIB MALATE vs SUVOREXANT SUNITINIB MALATE vs SUZETRIGINE SUNITINIB MALATE vs SYMBICORT

Related Pages

SUNITINIB MALATE Full Profile All Neoplasm progression Reports All Drugs Causing Neoplasm progression SUNITINIB MALATE Demographics